SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

Sagbo, G.G., Alao, M.J., Lalya, F.H., Dagbozounkou, B., Bagnan-Tossa, L., d’almeida, M. and Ayivi, B. (2012) Morbidity and Mortality of Childhood Severe Malaria in Six Hospitals of Benin. Bénin Médical, 50, 34-38.
https://doi.org/10.1016/S0140-6736(05)67176-0

has been cited by the following article:

  • TITLE: Benefits of Artesunate versus Quinine in the Treatment of Children with Severe Malaria at the National University Teaching Hospital of Cotonou

    AUTHORS: Godonou Gratien Sagbo, Laeticia Zohoun, Gilles Bognon, Joseph Agossou, Caroline Padonou, Yévèdo Tohodjèdé, Florence Alihonou, Blaise Ayivi

    KEYWORDS: Severe Malaria, Quinine, Artesunate

    JOURNAL NAME: Open Journal of Pediatrics, Vol.7 No.3, August 11, 2017

    ABSTRACT: Introduction: Severe malaria is one of the leading causes of death in Sub-Saharan African countries, and artesunate is recommended as a first-line treatment by the Word Heath Organization (WHO.). Objective: Identify the advantages of artesunate compared with quinine in the treatment of severe malaria in children. Methods and patients: This study was a cross-sectional, descriptive and analytical study focused on children hospitalized for severe malaria in the CNHU who were treated with quinine or artesunate. Findings: The hospital-based frequency rate of severe malaria in pediatric patients was estimated to be 28.3% (n = 848). One hundred five children were treated with artesunate, and 743 were treated with quinine. The mean age of the children was 47 months old. The primary signs of severity were anemia (n = 776), neurological manifestations (n = 309) and hemolysis (n = 137). The average duration of treatment was 1.95 days for artesunate versus 2.45 days for quinine, and the difference was statistically significant (p = 0.001). The average length of stay (ALOS) in the hospital was 5 days for the artesunate group versus 5.75 days for the quinine group, and the difference was statistically significant (p Conclusion: The treatment of severe malaria with artesunate is superior to quinine-based treatment.